Gadolinium-based contrast agent accumulation and toxicity: An update

American Journal of Neuroradiology

Volumn 37, Issue 7, 2016, Pages 1192-1198

  Ramalho, J ^a,b   Semelka, R C ^a   Ramalho, M ^a,c   Nunes, R H ^a,d   AlObaidy, M ^a,e   Castillo, M ^a  

^a UNIVERSITY OF NORTH CAROLINA HOSPITALS   (United States)

^b Universidade de Lisboa   (Portugal)

^c HOSPITAL GARCIA DE ORTA   (Portugal)

^d Santa Casa de Misericordia de Sao Paulo   (Brazil)

^e KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

Author keywords

DN=dentate nuclei; GBCA=gadolinium based contrast agent; NSF=nephrogenic systemic fibrosis

Indexed keywords

CONTRAST MEDIUM; GADOBENATE DIMEGLUMINE; GADOBUTROL; GADODIAMIDE; GADOFOSVESET; GADOLINIUM CHELATE; GADOLINIUM PENTETATE MEGLUMINE; GADOTERATE MEGLUMINE; GADOTERIDOL; GADOVERSETAMIDE; GADOXETIC ACID; GADOLINIUM;

BRAIN ATROPHY; CONTRAST ENHANCEMENT; DOSE RESPONSE; DRUG DISTRIBUTION; DRUG STABILITY; HEALTH CARE POLICY; HUMAN; IN VITRO STUDY; KIDNEY FUNCTION; MULTIPLE SCLEROSIS; NEPHROGENIC SYSTEMIC FIBROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; RADIATION DOSE; RADIATION DOSE REDUCTION; REVIEW; SEVERE RENAL IMPAIRMENT; ANIMAL; CEREBELLUM NUCLEUS; CHEMICALLY INDUCED; DIAGNOSTIC IMAGING;

ANIMALS; CEREBELLAR NUCLEI; CONTRAST MEDIA; GADOLINIUM; HUMANS; MAGNETIC RESONANCE IMAGING; NEPHROGENIC FIBROSING DERMOPATHY;

EID: 84978488402     PISSN: 01956108     EISSN: 1936959X     Source Type: Journal    
DOI: 10.3174/ajnr.A4615     Document Type: Review

References (67)

1. Hao D, Ai T, Goerner F, et al. MRI contrast agents: basic chemistry and safety. J Magn Reson Imaging 2012;36:1060-71 CrossRef Medline
2. Bleicher AG, Kanal E. Assessment of adverse reaction rates to a newly approved MRI contrast agent: review of 23,553 administrations of gadobenate dimeglumine. AJR Am J Roentgenol 2008;191: W307-11 CrossRef Medline
3. Kanal E, Tweedle MF. Residual or retained gadolinium: practical implications for radiologists and our patients. Radiology 2015;275: 630-34 CrossRef Medline
4. Ersoy H, Rybicki FJ. Biochemical safety profiles of gadoliniumbased extracellular contrast agents and nephrogenic systemic fibrosis. J Magn Reson Imaging 2007;26:1190-97 CrossRef Medline
5. Lin SP, Brown JJ. MR contrast agents: physical and pharmacologic basics. J Magn Reson Imaging 2007;25:884-99 CrossRef Medline
6. Gierada DS, Bae KT. Gadolinium as aCT contrast agent: assessment in a porcine model. Radiology 1999;210:829-34 CrossRef Medline
7. Quinn AD, O'Hare NJ, Wallis FJ, et al. Gd-DTPA: an alternative contrast medium for CT. J Comput Assist Tomogr 1994;18:634-36 CrossRef Medline
8. Henson JW, Nogueira RG, Covarrubias DJ, et al. Gadolinium-enhanced CT angiography of the circle of Willis and neck. AJNR Am J Neuroradiol 2004;25:969-72 Medline
9. Bonvento MJ, Moore WH, Button TM, et al. CT angiography with gadolinium-based contrast media. Acad Radiol 2006;13:979-85 CrossRef Medline
10. Grobner T. Gadolinium: a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant 2005;21:1104-08 CrossRef Medline
11. Marckmann P. Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol 2006;17:2359-62 CrossRef Medline
12. Thomsen HS. Nephrogenic systemic fibrosis: history and epidemiology. Radiol Clin North Am 2009;47:827-31, vi CrossRef Medline
13. Broome DR. Nephrogenic systemic fibrosis associated with gadolinium based contrast agents: a summary of the medical literature reporting. Eur J Radiol 2008;66:230-34 CrossRef Medline
14. Abujudeh HH, Kaewlai R, Kagan A, et al. Nephrogenic systemic fibrosis after gadopentetate dimeglumine exposure: case series of 36 patients. Radiology 2009;253:81-89 CrossRef Medline
15. Wertman R, Altun E, Martin DR, et al. Risk of nephrogenic systemic fibrosis: evaluation of gadolinium chelate contrast agents at four American universities. Radiology 2008;248:799-806 CrossRef Medline
16. Hope TA, Herfkens RJ, Denianke KS, et al. Nephrogenic systemic fibrosis in patients with chronic kidney disease who received gadopentetate dimeglumine. Invest Radiol 2009;44:135-39 CrossRef Medline
17. Fretellier N, Idée JM, Guerret S, et al. Clinical, biological, and skin histopathologic effects of ionic macrocyclic and nonionic linear gadolinium chelates in a rat model of nephrogenic systemic fibrosis. Invest Radiol 2011;46:85-93 CrossRef Medline
18. Kanda T, Ishii K, Kawaguchi H, et al. High signal intensity in the dentate nucleus and globus pallidus on unenhanced T1-weighted MR images: relationship with increasing cumulative dose of a gadolinium-based contrast material. Radiology 2014;270:834-41 CrossRef Medline
19. Errante Y, Cirimele V, Mallio CA, et al. Progressive increase of T1 signal intensity of the dentate nucleus on unenhanced magnetic resonance images is associated with cumulative doses of intravenously administered gadodiamide in patients with normal renal function, suggesting dechelation. Invest Radiol 2014;49:685-90 CrossRef Medline
20. Quattrocchi CC, Mallio CA, Errante Y, et al. Gadodiamide and dentate nucleus T1 hyperintensity in patients with meningioma evaluated by multiple follow-up contrast-enhanced magnetic resonance examinations with no systemic interval therapy. Invest Radiol 2015; 50:470-72 CrossRef Medline
21. Ramalho J, Castillo M, AlObaidy M, et al. High signal intensity in globus pallidus and dentate nucleus on unenhanced T1-weighted MR images: evaluation of two linear gadolinium-based contrast agents. Radiology 2015;276:836-44 CrossRef Medline
22. Kanda T, Osawa M, Oba H, et al. High signal intensity in dentate nucleus on unenhanced T1-weighted MR images: association with linear versus macrocyclic gadolinium chelate administration. Radiology 2015;275:803-09 CrossRef Medline
23. Roccatagliata L, Vuolo L, Bonzano L, et al. Multiple sclerosis: hyperintense dentate nucleus on unenhanced T1-weighted MR images is associated with the secondary progressive subtype. Radiology 2009; 251:503-10 CrossRef Medline
24. Kasahara S, Miki Y, Kanagaki M, et al. Hyperintense dentate nucleus on unenhanced T1-weightedMRimages is associated with a history of brain irradiation. Radiology 2011;258:222-28 CrossRef Medline
25. Adin ME, Kleinberg L, Vaidya D, et al. Hyperintense dentate nuclei on T1-weighted MRI: relation to repeat gadolinium administration. AJNR Am J Neuroradiol 2015;36:1859-65 CrossRef Medline
26. McDonald RJ, McDonald JS, Kallmes DF, et al. Intracranial gadolinium deposition after contrast-enhanced MR imaging. Radiology 2015;275:772-82 CrossRef Medline
27. Kanda T, Fukusato T, Matsuda M, et al. Gadolinium-based contrast agent accumulates in the brain even in subjects without severe renal dysfunction: evaluation of autopsy brain specimens with inductively coupled plasma mass spectroscopy. Radiology 2015;276: 228-32 CrossRef Medline
28. Robert P, Lehericy S, Grand S, et al. T1-weighted hypersignal in the deep cerebellar nuclei after repeated administrations of gadolinium-based contrast agents in healthy rats: difference between linear and macrocyclic agents. Invest Radiol 2015;50:473-80 CrossRef Medline
29. Radbruch A, Weberling LD, Kieslich PJ, et al. Gadolinium retention in the dentate nucleus and globus pallidus is dependent on the class of contrast agent. Radiology 2015;275:783-91 CrossRef Medline
30. Weberling LD, Kieslich PJ, Kickingereder P, et al. Increased signal intensity in the dentate nucleus on unenhanced T1-weighted images after gadobenate dimeglumine administration. Invest Radiol 2015:50:743-48 CrossRef Medline
31. Stojanov DA, Aracki-Trenkic A, Vojinovic S, et al. Increasing signal intensity within the dentate nucleus and globus pallidus on unenhancedT1Wmagnetic resonance images in patients with relapsingremitting multiple sclerosis: correlation with cumulative dose of a macrocyclic gadolinium-based contrast agent, gadobutrol. Eur Radiol 2015 Jun 25 [Epub ahead of print] Medline
32. de Campos RO, Herédia V, Ramalho M, et al. Application of gadolinium based contrast agents in abdominal magnetic resonance imaging: important considerations. In: Thompson CC, ed. Gadolinium: Compounds, Production and Applications. New York: Nova Science Publishers; 2009:chap 5
33. Frenzel T, Lengsfeld P, Schirmer H, et al. Stability of gadoliniumbased magnetic resonance imaging contrast agents in human serum at 37 degrees C. Invest Radiol 2008;43:817-28 CrossRef Medline
34. Idée JM, Port M, Robic C, et al. Role of thermodynamic and kinetic parameters in gadolinium chelate stability. J Magn Reson Imaging 2009;30:1249-58 CrossRef Medline
35. Prince MR, Erel HE, Lent RW, et al. Gadodiamide administration causes spurious hypocalcemia. Radiology 2003;227:639-46 CrossRef Medline
36. Laurent S, Elst LV, Copoix F, et al. Stability of MRI paramagnetic contrast media: a proton relaxometric protocol for transmetallation assessment. Invest Radiol 2001;36:115-22 CrossRef Medline
37. Tweedle MF, Wedeking P, Kumar K. Biodistribution of radiolabeled, formulated gadopentetate, gadoteridol, gadoterate, and gadodiamide in mice and rats. Invest Radiol 1995;30:372-80 CrossRef Medline
38. Tweedle MF, Hagan JJ, Kumar K, et al. Reaction of gadolinium chelates with endogenously available ions. Magn Reson Imaging 1991;9: 409-15 CrossRef Medline
39. Corot C, Idée JM, Hentsch AM, et al. Structure-activity relationship of macrocyclic and linear gadolinium chelates: investigation of transmetallation effect on the zinc-dependent metallopeptidase angiotensin-converting enzyme. J Magn Reson Imaging 1998;8:695-702 CrossRef Medline
40. Aime S, Caravan P. Biodistribution of gadolinium-based contrast agents, including gadolinium deposition. J Magn Reson Imaging 2009;30:1259-67 CrossRef Medline
41. Altum E, Semelka RC, Cakit C. Nephrogenic systemic fibrosis and management of high-risk patients. Acad Radiol 2009;16:897-905 CrossRef Medline
42. Quarles LD, Hartle JE 2nd, Middleton JP, et al. Aluminum-induced DNA synthesis in osteoblasts: mediation by a G-protein coupled cation sensing mechanism. J Cell Biochem 1994;56:106-17 CrossRef Medline
43. Pa?asz A, Czekaj P. Toxicological and cytophysiological aspects of lanthanides action. Acta Biochim Pol 2000;47:1107-14 Medline
44. Feng X, Xia Q, Yuan L, et al. Impaired mitochondrial function and oxidative stress in rat cortical neurons: implications for gadoliniuminduced neurotoxicity. Neurotoxicology 2010;31:391-98 CrossRef Medline
45. Xia Q, Feng X, Huang H, et al. Gadolinium-induced oxidative stress triggers endoplasmic reticulum stress in rat cortical neurons. J Neurochem 2011;117:38-47 CrossRef Medline
46. Spencer AJ, Wilson SA, Batchelor J, et al. Gadolinium chloride toxicity in the rat. Toxicol Pathol 1997;25:245-55 CrossRef Medline
47. Idée JM, Port M, Medina C, et al. Possible involvement of gadolinium chelates in the pathophysiology of nephrogenic systemic fibrosis: a critical review. Toxicology 2008;248:77-88 CrossRef Medline
48. Piera-Velazquez S, Louneva N, Fertala J, et al. Persistent activation of dermal fibroblasts from patients with gadolinium-associated nephrogenic systemic fibrosis. Ann Rheum Dis 2010;69:2017-23 CrossRef Medline
49. Bhagavathula N, Dame MK, DaSilva M, et al. Fibroblast response to gadolinium: role for platelet-derived growth factor receptor. Invest Radiol 2010;45:769-77 CrossRef Medline
50. Edward M, Quinn JA, Burden AD, et al. Effect of different classes of gadolinium-based contrast agents on control and nephrogenic systemic fibrosis-derived fibroblast proliferation. Radiology 2010;256: 735-43 CrossRef Medline
51. Varani J, DaSilva M, Warner RL, et al. Effects of gadolinium-based magnetic resonance imaging contrast agents on human skin in organ culture and human skin fibroblasts. Invest Radiol 2009;44: 74-81 CrossRef Medline
52. Christensen KN, Lee CU, Hanley MM, et al. Quantification of gadolinium in fresh skin and serum samples from patients with nephrogenic systemic fibrosis. J Am Dermatol 2011;64:91-96 CrossRef Medline
53. Cowper SE, Bucala R, Leboit PE. Nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis: setting the record straight. Semin Arthritis Rheum 2006;35:208-10 CrossRef Medline
54. Gibby WA, Gibby KA, Gibby WA. Comparison of Gd DTPA-BMA (Omniscan) versus Gd HP-DO3A (ProHance) retention in human bone tissue by inductively coupled plasma atomic emission spectroscopy. Invest Radiol 2004;39:138-42 CrossRef Medline
55. White GW, Gibby WA, Tweedle MF. Comparison of Gd(DTPABMA) (Omniscan) versus Gd(HP-DO3A) (ProHance) relative to gadolinium retention in human bone tissue by inductively coupled plasma mass spectroscopy. Invest Radiol 2006;41:272-78 CrossRef Medline
56. Darrah TH, Prutsman-Pfeiffer JJ, Poreda RJ, et al. Incorporation of excess gadolinium into human bone from medical contrast agents. Metallomics 2009;1:479-88 CrossRef Medline
57. Rocklage SM, Worah D, Kim SH. Metal ion release from paramagnetic chelates: what is tolerable? Magn Reson Med 1991;22:216-21; discussion 229-32 CrossRef Medline
58. Abraham JL, Thakral C, Skov L, et al. Dermal inorganic gadolinium concentrations: evidence for in vivo transmetallation and longterm persistence in nephrogenic systemic fibrosis. Br J Dermatol 2008;158:273-80 Medline
59. Xia D, Davis RL, Crawford JA, et al. Gadolinium released from MR contrast agents is deposited in brain tumors: in situ demonstration using scanning electron microscopy with energy dispersive X-ray spectroscopy. Acta Radiol 2010;51:1126-36 CrossRef Medline
60. Sanyal S, Marckmann P, Scherer S, et al. Multiorgan gadolinium (Gd) deposition and fibrosis in a patient with nephrogenic systemic fibrosis: an autopsy-based review. Nephrol Dial Transplant 2011;26: 3616-26 CrossRef Medline
61. Ogi S, Fukumitsu N, Tsuchida D, et al. Imaging of bilateral striopallidodentate calcinosis. Clin Nucl Med 2002;27:721-24 CrossRef Medline
62. Fretellier N, Idée JM, Dencausse A, et al. Comparative in vivo dissociation of gadolinium chelates in renally impaired rats: a relaxometry study. Invest Radiol 2011;46:292-300 CrossRef Medline
63. Schroeder JA, Weingart C, Coras B, et al. Ultrastructural evidence of dermal gadolinium deposits in a patient with nephrogenic systemic fibrosis and end-stage renal disease. Clin J Am Soc Nephrol 2008;3: 968-75 CrossRef Medline
64. Thakral C, Abraham JL. Gadolinium-induced nephrogenic systemic fibrosis is associated with insoluble Gd deposits in tissues: in vivo transmetallation confirmed by microanalysis. J Cutan Pathol 2009; 36:1244-54 CrossRef Medline
65. Ray DE, Holton JL, Nolan CC, et al. Neurotoxic potential of gadodiamide after injection into the lateral cerebral ventricle of rats. AJNR Am J Neuroradiol 1998;19:1455-62 Medline
66. Roman-Goldstein SM, Barnett PA, McCormick CI, et al. Effects of gadopentetate dimeglumine administration after osmotic bloodbrain barrier disruption: toxicity and MR imaging findings. AJNR Am J Neuroradiol 1991;12:885-90 Medline
67. Gadolinium Toxicity: A Survey of the Chronic Effects of Retained Gadolinium from Contrast MRIs. https://gdtoxicity. files. wordpress. com/2014/09/gd-symptom-survey. pdf. Accessed September 1, 2015